AbCellera Launches $200M Stock Offering Days After Phase 2 Win
ABCL has more than doubled off its 52-week low of $2.745 on elevated volume (2.1× avg).
Summary
AbCellera is selling $200M in common stock and pre-funded warrants, just one day after its ABCL635 Phase 2 success sent shares higher. The offering capitalizes on the stock's recent strength but will dilute existing holders. Proceeds are earmarked for pipeline development, including the lead menopause drug, and general corporate purposes. The timing is aggressive—the company just reported $84M in upfront payments and extended its cash runway, so this raise is opportunistic rather than a rescue. Jefferies, J.P. Morgan, and others are underwriting; terms and pricing are not yet set. The move signals management is seizing a window to fund operations, but the dilution overhang could pressure the stock.
At the time of this announcement, ABCL was trading at $9.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $2.75 to $10.29. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.